Showing posts with label everolimus. Show all posts
Showing posts with label everolimus. Show all posts
Thursday, April 20, 2017

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

›
In continuation of my update on  everolimus The targeted therapy everolimus may be safely combined with R-CHOP for new, untrea...
Thursday, May 19, 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

›
  In continuation of my update  on   Everolimus   Novartis today announced that the United States Food and Drug Administration (FD...
Monday, November 2, 2015

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

›
  Positive progression-free survival (PFS) results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians tr...
Thursday, August 1, 2013

Drug shows dramatic reduction in seizures in patients with tuberous sclerosis complex

›
In continuation of my update on  Everolimus Newest study, led by a physician-scientist at Cincinnati Children's in collabora...
Sunday, February 3, 2013

Everolimus treatment option for tuberous sclerosis patients

›
In continuation of my update on Everolimus Everolimus treatment option for tuberous sclerosis patients
Wednesday, December 19, 2012

Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic

›
In continuation of my update on  Everolimus Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic ...
Thursday, November 22, 2012

Drug shrinks brain tumors in children with tuberous sclerosis complex, study suggests

›
In continuation of my update on   Everolimus   "Every patient in this study experienced a decrease in size of their tumo...
Saturday, May 12, 2012

Combination of Two Drugs Reverses Liver Tumors.....

›
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study...
1 comment:
Friday, June 4, 2010

RADIANT-3 study results show everolimus significantly extends progression-free survival in patients with advanced pancreatic neuroendocrine tumors...

›
We know that Everolimus ( RAD-001 , marketed by Novartis under the  tradenames Zortress (USA) and Certican (Europe and other coun...